MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, PVLA had -$25,620K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$25,620K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Stock-based compensation
    • Non-cash interest expense - roya...
    • German research and development ...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accrued expenses and other curre...
    • Payment of transaction costs in ...
    • Deferred equity issuance costs

Cash Flow
2025-12-31
Net loss
-41,715
Non-cash interest expense - royalty agreement
5,818
Non-cash interest expense - convertible notes
0
Change in fair value of derivative liabilities - royalty agreement
394
Change in fair value of derivative liabilities - contingent value right liability
218
Change in fair value of convertible notes payable
0
Stock-based compensation
6,401
Non-cash lease operating expense
62
Costs to issue convertible notes
0
Accounts receivable
-387
German research and development tax credit receivable
-2,105
Prepaid expenses and other current assets
-1,364
Account payable
1,260
Accrued expenses and other current liabilities
-1,300
Net cash used in operating activities
-25,006
Cash acquired from reverse merger transaction
0
Payment of transaction costs in connection with reverse merger
1,269
Proceeds from pipe financing
0
Payments of transaction costs associated with pipe financing
0
Proceeds from issuance of convertible notes
0
Payment of transaction costs to issue convertible notes
0
Proceeds from exercise of stock options
763
Deferred equity issuance costs
154
Net cash (used in) provided by financing activities
-660
Effect of exchange rate change on cash and cash equivalents
46
Net (decrease) increase in cash and cash equivalents
-25,620
Cash and cash equivalents at beginning of period
83,602
Cash and cash equivalents at end of period
57,982
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Effect of exchange ratechange on cash and cash...$46K Net (decrease)increase in cash and cash...-$25,620K Canceled cashflow$46K Stock-based compensation$6,401K Non-cash interestexpense - royalty...$5,818K German research anddevelopment tax credit...-$2,105K Prepaid expenses andother current assets-$1,364K Account payable$1,260K Change in fair value ofderivative liabilities -...$394K Accounts receivable-$387K Change in fair value ofderivative liabilities -...$218K Non-cash lease operatingexpense$62K Proceeds from exercise ofstock options$763K Net cash used inoperating activities-$25,006K Net cash (used in)provided by financing...-$660K Canceled cashflow$18,009K Canceled cashflow$763K Net loss-$41,715K Payment of transactioncosts in connection...$1,269K Accrued expenses andother current...-$1,300K Deferred equity issuancecosts$154K

PALVELLA THERAPEUTICS, INC. (PVLA)

PALVELLA THERAPEUTICS, INC. (PVLA)